Business
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc(“Arecor” or the “Company”) Co-development Agreement with US Insulin Pump Device Company for AT278 andSale of Royalty and Technology Access Fees for up to $11 million AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturi
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").","length":159,"tagName":"p"},{"type":"text","content":"Arecor Therapeutics plc(“Arecor” or the “Company”)","length":51,"tagName":"p"},{"type":"text","content":"Co-development Agreement with US Insulin Pump Device Company for AT278 andSale of Royalty and Technology Access Fees for up to $11 million ","length":140,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems ","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Arecor and Sequel Med Tech, LLC to commit up to $1.3 million each to fund development work in preparation for pivotal Phase 2 trial for AT278-Insulin Pump programme","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic intent is to progress to a broader co-development and commercialisation partnership for Phase 2 trial and beyond","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-dilutive funds raised through the monetisation of Arecor’s royalty rights related to AT220 and milestone and technology access fees related to AT292","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway extended to 1H 2027 ","length":31,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":673,"olType":false},{"type":"text","content":"Cambridge, UK, 25 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, has signed a co-development agreement with Sequel Med Tech LLC (“Sequel”), a company developing state-of-the-art insulin delivery technologies, to combine AT278 (500U/mL) with Sequel’s twiist™ Automated Insulin Delivery (AID) system powered by Tidepool, and a royalty financing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand”) which will raise non-dilutive capital of up to $11 million (£8.2 million).","length":619,"tagName":"p"},{"type":"text","content":"Sarah Howell, CEO of Arecor Therapeutics said: ","length":46,"tagName":"p"},{"type":"te...